Vietnamese herbal medicine (TD0019) in the treatment of cervical radiculopathy: A double-blind phase-2 randomized controlled trial

被引:1
作者
Ha, Nguyen Thi Thu [1 ]
Vuong, Nguyen Lam [2 ]
Lua, Trinh Thi [1 ]
Nguyen, Trang Thi Minh [2 ]
Nghia, Duong Trong [3 ]
Nga, Ha Thi Viet [3 ]
Anh, Pham Thi Van [4 ]
Truc, Thai Thanh [2 ]
Dung, Do Van [2 ]
机构
[1] Hanoi Med Univ, Fac Tradit Med, Hanoi, Vietnam
[2] Univ Med & Pharm Ho Chi Minh City, Fac Publ Hlth, Dept Med Stat & Informat, 217 Hong Bang St,Ward 11,Dist 5, Ho Chi Minh City, Vietnam
[3] Natl Hosp Tradit Med, Hanoi, Vietnam
[4] Hanoi Med Univ, Dept Pharmacol, Hanoi, Vietnam
关键词
Cervical radiculopathy; Intervertebral disc degeneration; Neck disability index; Vietnamese herbal medicine formula; TD0019; Randomized controlled trial; NECK PAIN; EPIDEMIOLOGY;
D O I
10.1016/j.eujim.2020.101060
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Introduction: Cervical radiculopathy causes chronic pain and reduces patients' quality of life. Oral analgesics are commonly used but only after careful consideration due to their complications. TD0019, a Vietnamese herbal medicine, composed of Duhuo Jisheng decoction, nattokinase and an extract of Salix alba cortex has shown evidence of some benefits for these patients in pre-clinical and phase-1 studies. This study aimed to evaluate the efficacy and safety of TD0019 in the treatment of cervical radiculopathy. Methods: In this double-blind phase-2 trial, 180 patients with symptomatic cervical radiculopathy were randomized to either group 1 with intended dose of TD0019, group 2 with a higher dose (1.5 times the intended dose), or group 3, a placebo. The primary efficacy endpoint was the neck-specific disability score according to the Neck Disability Index (NDI) questionnaire. The safety endpoint included adverse events (AEs) and serious adverse events (SAEs). All patients received the drugs for 30 days and were followed for 60 days. Results: Baseline characteristics were similar for the three groups. The reduction of NDI score from baseline to the end of study was greatest for group 2 (from 17.6 +/- 7.2 to 4.8 +/- 5.1), followed by group 1 (from 16.1 +/- 6.9 to 5.4 +/- 5.1) and placebo group (from 15.6 +/- 6.2 to 7.8 +/- 6.8), with a significant decrease for both groups compared to placebo. The percentage of AEs was comparable among three groups and no SAEs occurred. Conclusions: TD0019 was superior to placebo for the reduction of symptoms with similar rates of side effects. The higher dose is more beneficial than the intended dose. This herbal medicine may be a potential alternative analgesic in the treatment of cervical radiculopathy.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double-blind, placebo-controlled trial
    Kotajima-Murakami, Hiroko
    Takano, Ayumi
    Hirakawa, Shinya
    Ogai, Yasukazu
    Funada, Daisuke
    Tanibuchi, Yuko
    Ban, Eriko
    Kikuchi, Minako
    Tachimori, Hisateru
    Maruo, Kazushi
    Kawashima, Takahiro
    Tomo, Yui
    Sasaki, Tsuyoshi
    Oi, Hideki
    Matsumoto, Toshihiko
    Ikeda, Kazutaka
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2022, 42 (01) : 92 - 104
  • [42] Efficacy of Individualized Homeopathic Medicines in the Treatment of Hemorrhoids: Double-Blind, Randomized, Placebo-Controlled Trial
    Koley, Munmun
    Vimal, Vinod Kumar
    Verma, Arvind Kumar
    Pal, Shiv Shanker
    Sonkar, Dileep Kumar
    Vimal, Smita
    Singh, Om Prakash
    Ghosh, Shubhamoy
    Saha, Subhranil
    JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE, 2024, 30 (08): : 783 - 792
  • [43] Oral Huzhang granules for the treatment of acute gouty arthritis: protocol for a double-blind, randomized, controlled trial
    Mi Zhou
    Liang Hua
    Yi-Fei Wang
    Si-Ting Chen
    Chun-mei Yang
    Ming Zhang
    Xin Li
    Bin Li
    Trials, 23
  • [44] Can moxibustion, an ancient treatment modality, be evaluated in a double-blind randomized controlled trial? —— A narrative review
    Bai-xiao Zhao
    Hai-Yong Chen
    Xue-yong Shen
    Lixing Lao
    Journal of Integrative Medicine, 2014, (03) : 131 - 134
  • [45] Can moxibustion, an ancient treatment modality, be evaluated in a double-blind randomized controlled trial? - A narrative review
    Zhao, Bai-xiao
    Chen, Hai-yong
    Shen, Xue-yong
    Lao, Lixing
    JOURNAL OF INTEGRATIVE MEDICINE-JIM, 2014, 12 (03): : 131 - 134
  • [46] Individualized homeopathic medicines in the treatment of premenstrual syndrome: A double-blind, randomized, placebo-controlled trial
    Sahoo, Sanjib
    Nayak, Chintamani
    Rath, Prasanta
    Bhattacharya, Soumya
    Mukherjee, Suranjana
    Dutta, Abhijit
    EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2024, 20 (06)
  • [47] Individualized Homeopathic Medicines in Treatment of Hyperuricemia: Evaluation by Double-Blind, Randomized, Placebo-Controlled Trial
    Ghosh, Priyanka
    Ganguly, Subhasish
    Mukherjee, Shyamal Kumar
    Dutta, Souvik
    Shaikh, Abdur Rahaman
    Ali, Sk Swaif
    Singh, Navin Kumar
    Bhattacharya, Pulakendu
    Koley, Munmun
    Saha, Subhranil
    HOMEOPATHY, 2023, 112 (02) : 85 - 96
  • [48] A Dietary Fiber Mixture versus Lactulose in the Treatment of Childhood Constipation: A Double-blind Randomized Controlled Trial
    Kokke, Freddy T. M.
    Scholtens, Petra A. M. J.
    Alles, Martine S.
    Decates, Tom S.
    Fiselier, Theo J. W.
    Tolboom, Jules J. M.
    Kimpen, Jan L. L.
    Benninga, Marc A.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2008, 47 (05) : 592 - 597
  • [49] N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial
    Morley, Kirsten C.
    Peruch, Siena
    Adams, Claire
    Towers, Ellen
    Tremonti, Chris
    Watt, Joshua
    Jamshidi, Nazila
    Haber, Paul S.
    ALCOHOL AND ALCOHOLISM, 2023, 58 (05): : 553 - 560
  • [50] Dietary therapy of the herbal porridge improves the symptoms of functional dyspepsia: A randomized, double-blind, placebo-controlled, clinical trial
    Wang, Xin
    Liu, Meng-Ao
    He, Jia
    Zhao, Wen-Zhi
    Wang, Yi-Xuan
    Yang, Liu-Qing
    Wang, Tian-Yuan
    Shi, Han-Ping
    Rao, Ben-Qiang
    FOOD SCIENCE & NUTRITION, 2024, 12 (03): : 2104 - 2114